Fig. 3: ANGPTL8KO enhanced hypertrophic and fibrotic marker expression after Ang II infusion for 4 weeks.
From: ANGPTL8 is a negative regulator in pathological cardiac hypertrophy
Representative images of H&E staining (A), WGA staining (B), picrosirius red (PSR) staining (C) and collagen I staining (D) of slices from transverse sections of the left ventricles from the mouse hearts in the indicated groups (n = 5 mice per group, scale bars, 250 μm and 100 μm, respectively). Quantification of the average myocardial interstitial area (E) and myocyte cross-sectional areas (F) in WT and ANGPTL8-KO mice at 4 weeks (E n > 40 fields and F n = 100 cardiomyocytes from 5~6 mice in each group, NS no significant difference, **P < 0.01, ***P < 0.001). G Quantitative results of the collagen I-positive area from collagen I immunochemical staining in WT and ANGPTL8-KO mice (n = 5 mice in each group, **P < 0.01). H, I mRNA levels of ANF and BNP were analyzed by qRT–PCR from WT and ANGPTL8-KO mouse hearts (n = 5 mice in each group). J Representative Western blots of β-MHC and BNP in cardiac tissue from WT and ANGPTL8-KO mice (n = 3). K, L Quantitative statistical results of β-MHC and BNP protein levels (n = 3, NS no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001).
